Gene expression profiling based identification of DKK1 as a...

Details Gene expression profiling based identification of DKK1 as a... Gene expression profiling based identification of DKK1 as a...

2008-05-13

2008-05-13

Zhou, Shubo (Joe) (Department: 1631)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S139100, C435S006120, C514S130000

Reexamination Certificate

active

10931780

ABSTRACT:
Gene expression profiling reveals four distinct subgroups of multiple myeloma that have significant correlation with various clinical characteristics. Diagnosis for multiple myeloma (and possibly monoclonal gammopathy of undetermined significance) based on differential expression of 14 genes, as well as prognosis for the four subgroups of multiple myeloma based on the expression of 24 genes are established. A 15-gene model that classifies myeloma into 7 groups is also reported. Gene expression profiling also allows placing multiple myeloma into a developmental schema parallel to that of normal plasma cell differentiation. Development of a gene expression- or developmental stage-based classification system for multiple myeloma would lead to rational design of more accurate and sensitive diagnostics, prognostics and tumor-specific therapies for multiple myeloma.

Affiliated with

Also associated with

Rating

Gene expression profiling based identification of DKK1 as a... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gene expression profiling based identification of DKK1 as a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene expression profiling based identification of DKK1 as a... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3943783